Showing 3461-3470 of 5063 results for "".
A Meeting for Treating the Whole Person
https://practicaldermatology.com/conferences/noah-worcester/a-meeting-for-treating-the-whole-person/57065/Stan Tolkachjov, MD, Scientific Program Co-chair for the Noah Worcester Dermatological Society’s 2026 Annual Meeting, explains what he and Co-chair David Wetter, MD, sought to accomplish with this year’s presentations.Improving Care Options for CTCL
https://practicaldermatology.com/videos/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.DWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.DermwireTV 2024 Year in Review
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-2024-year-in-review/32206/We look back at the top stories of 2024 in the Dermatology and Aesthetics markets. Several new products were approved or launched in atopic dermatitis, rosacea, prurigo nodularis, and hidradenitis suppurativa; new clinical guidelines were made for AD, acne care, and skin cancer; and a new study raisDermWireTV: Diagnosing Melanoma Using Deep-Learning Model; New Adbry Approval
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-diagnosing-melanoma-using-deep-learning-model-new-adbry-approval/26445/In this week's DermWireTV, researchers develop a novel deep-learning model designed to more accurately diagnose melanoma; LEO Pharma receives a new approval for atopic dermatitis drug Adbry; and in our PA Perspectives segment, Andrew Mastro discusses how to build an inflammatory clinic.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisScientifically Speaking: Investing in Innovation with Humberto Antunes
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-investing-in-innovation-with-humberto-antunes/20128/With decades of experience in dermatology and aesthetics, Humberto Antunes has helped to identify some key innovations in the field. Now part of Gore Range Capital, he continues to look for the next game-changer. He discusses his experience and shares insights on the specialties with host Joel L. CoDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibilityPsoriasis and Inflammatory Disease Management Today
https://practicaldermatology.com/topics/psoriasis/psoriasis-and-inflammatory-disease-management-today/19885/COVID-19 can have implications for psoriasis management. Jashin Wu, MD, founder of San Diego Dermatology Symposium, provides guidance on management and introduces the Inaugural Symposium for Inflammatory Skin Disease, coming virtually in April.Evolutions and Revolutions in HS
https://practicaldermatology.com/topics/rare-disease/evolutions-and-revolutions-in-hs/19726/The past decade has seen significant advances in the understanding of hidradenitis suppurativa pathogenesis, informing research into novel treatment approaches, such as biologics, and expanded indications for existing pharmacologic agents. Ali Alikhan, MD reviews the evolving landscape in HS and rev